122 related articles for article (PubMed ID: 30954941)
1. Preclinical Characterization of
Grudzinski JJ; Hernandez R; Marsh I; Patel RB; Aluicio-Sarduy E; Engle J; Morris Z; Bednarz B; Weichert J
J Nucl Med; 2019 Nov; 60(11):1622-1628. PubMed ID: 30954941
[TBL] [Abstract][Full Text] [Related]
2.
Hernandez R; Grudzinski JJ; Aluicio-Sarduy E; Massey CF; Pinchuk AN; Bitton AN; Patel R; Zhang R; Rao AV; Iyer G; Engle JW; Weichert JP
J Nucl Med; 2020 Aug; 61(8):1187-1194. PubMed ID: 31862799
[TBL] [Abstract][Full Text] [Related]
3.
Hernandez R; Walker KL; Grudzinski JJ; Aluicio-Sarduy E; Patel R; Zahm CD; Pinchuk AN; Massey CF; Bitton AN; Brown RJ; Sondel PM; Morris ZS; Engle JW; Capitini CM; Weichert JP
Commun Biol; 2019; 2():79. PubMed ID: 30820474
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and Biodistribution of (86)Y-Trastuzumab for (90)Y dosimetry in an ovarian carcinoma model: correlative MicroPET and MRI.
Palm S; Enmon RM; Matei C; Kolbert KS; Xu S; Zanzonico PB; Finn RL; Koutcher JA; Larson SM; Sgouros G
J Nucl Med; 2003 Jul; 44(7):1148-55. PubMed ID: 12843231
[TBL] [Abstract][Full Text] [Related]
5. Preclinical evaluation of 86Y-labeled inhibitors of prostate-specific membrane antigen for dosimetry estimates.
Banerjee SR; Foss CA; Pullambhatla M; Wang Y; Srinivasan S; Hobbs RF; Baidoo KE; Brechbiel MW; Nimmagadda S; Mease RC; Sgouros G; Pomper MG
J Nucl Med; 2015 Apr; 56(4):628-34. PubMed ID: 25722448
[TBL] [Abstract][Full Text] [Related]
6. Temporal analysis of type 1 interferon activation in tumor cells following external beam radiotherapy or targeted radionuclide therapy.
Jagodinsky JC; Jin WJ; Bates AM; Hernandez R; Grudzinski JJ; Marsh IR; Chakravarty I; Arthur IS; Zangl LM; Brown RJ; Nystuen EJ; Emma SE; Kerr C; Carlson PM; Sriramaneni RN; Engle JW; Aluicio-Sarduy E; Barnhart TE; Le T; Kim K; Bednarz BP; Weichert JP; Patel RB; Morris ZS
Theranostics; 2021; 11(13):6120-6137. PubMed ID: 33995649
[No Abstract] [Full Text] [Related]
7. Next-Generation Cancer Magnetic Resonance Imaging With Tumor-Targeted Alkylphosphocholine Metal Analogs.
Zhang RR; Choi C; Brunnquell CL; Hernandez R; Pinchuk AN; Grudzinski JG; Clark PA; McMillan AB; Audhya A; Jeffrey J; Kuo JS; Weichert JP
Invest Radiol; 2022 Oct; 57(10):655-663. PubMed ID: 36069439
[TBL] [Abstract][Full Text] [Related]
8. Safety and feasibility of an in situ vaccination and immunomodulatory targeted radionuclide combination immuno-radiotherapy approach in a comparative (companion dog) setting.
Magee K; Marsh IR; Turek MM; Grudzinski J; Aluicio-Sarduy E; Engle JW; Kurzman ID; Zuleger CL; Oseid EA; Jaskowiak C; Albertini MR; Esbona K; Bednarz B; Sondel PM; Weichert JP; Morris ZS; Hernandez R; Vail DM
PLoS One; 2021; 16(8):e0255798. PubMed ID: 34383787
[TBL] [Abstract][Full Text] [Related]
9. Low-Dose Radiation Potentiates the Propagation of Anti-Tumor Immunity against Melanoma Tumor in the Brain after In Situ Vaccination at a Tumor outside the Brain.
Clark PA; Sriramaneni RN; Bates AM; Jin WJ; Jagodinsky JC; Hernandez R; Le T; Jeffery JJ; Marsh IR; Grudzinski JJ; Aluicio-Sarduy E; Barnhart TE; Anderson BR; Chakravarty I; Arthur IS; Kim K; Engle JW; Bednarz BP; Weichert JP; Morris ZS
Radiat Res; 2021 Jun; 195(6):522-540. PubMed ID: 33826741
[TBL] [Abstract][Full Text] [Related]
10. Low-dose targeted radionuclide therapy renders immunologically cold tumors responsive to immune checkpoint blockade.
Patel RB; Hernandez R; Carlson P; Grudzinski J; Bates AM; Jagodinsky JC; Erbe A; Marsh IR; Arthur I; Aluicio-Sarduy E; Sriramaneni RN; Jin WJ; Massey C; Rakhmilevich AL; Vail D; Engle JW; Le T; Kim K; Bednarz B; Sondel PM; Weichert J; Morris ZS
Sci Transl Med; 2021 Jul; 13(602):. PubMed ID: 34261797
[TBL] [Abstract][Full Text] [Related]
11. Biodistribution, Pharmacokinetics, and Dosimetry of
Nicolas GP; Mansi R; McDougall L; Kaufmann J; Bouterfa H; Wild D; Fani M
J Nucl Med; 2017 Sep; 58(9):1435-1441. PubMed ID: 28450554
[TBL] [Abstract][Full Text] [Related]
12. Administration Routes for SSTR-/PSMA- and FAP-Directed Theranostic Radioligands in Mice.
Klose JM; Wosniack J; Iking J; Staniszewska M; Zarrad F; Trajkovic-Arsic M; Herrmann K; Costa PF; Lueckerath K; Fendler WP
J Nucl Med; 2022 Sep; 63(9):1357-1363. PubMed ID: 34992151
[TBL] [Abstract][Full Text] [Related]
13. Radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-DOTA humanized anti-CD22 IgG (90Y-Epratuzumab): do tumor targeting and dosimetry predict therapeutic response?
Sharkey RM; Brenner A; Burton J; Hajjar G; Toder SP; Alavi A; Matthies A; Tsai DE; Schuster SJ; Stadtmauer EA; Czuczman MS; Lamonica D; Kraeber-Bodere F; Mahe B; Chatal JF; Rogatko A; Mardirrosian G; Goldenberg DM
J Nucl Med; 2003 Dec; 44(12):2000-18. PubMed ID: 14660727
[TBL] [Abstract][Full Text] [Related]
14. Cyclotron-Produced
Aluicio-Sarduy E; Barnhart TE; Weichert J; Hernandez R; Engle JW
J Nucl Med; 2021 Jul; 62(7):1012-1015. PubMed ID: 33127622
[TBL] [Abstract][Full Text] [Related]
15. Preclinical Characterization of the Radioimmunoconjugate
Funase Y; Nakamura E; Kajita M; Saito Y; Oshikiri S; Kitano M; Tokura M; Hino A; Uehara T
J Nucl Med; 2021 Feb; 62(2):232-239. PubMed ID: 32737245
[TBL] [Abstract][Full Text] [Related]
16. Intratumorally Injected 177Lu-Labeled Gold Nanoparticles: Gold Nanoseed Brachytherapy with Application for Neoadjuvant Treatment of Locally Advanced Breast Cancer.
Yook S; Cai Z; Lu Y; Winnik MA; Pignol JP; Reilly RM
J Nucl Med; 2016 Jun; 57(6):936-42. PubMed ID: 26848176
[TBL] [Abstract][Full Text] [Related]
17. Targeting of Head and Neck Cancer by Radioiodinated CLR1404 in Murine Xenograft Tumor Models with Partial Volume Corrected Theranostic Dosimetry.
Marsh IR; Li C; Grudzinski J; Jeffery J; Longhurst C; Adam DP; Hernandez R; Weichert JP; Harari PM; Bednarz BP
Cancer Biother Radiopharm; 2023 Sep; 38(7):458-467. PubMed ID: 37022739
[No Abstract] [Full Text] [Related]
18. Antitumor efficacy of
Potluri HK; Ferreira CA; Grudzinski J; Massey C; Aluicio-Sarduy E; Engle JW; Kwon O; Marsh IR; Bednarz BP; Hernandez R; Weichert JP; McNeel DG
J Immunother Cancer; 2022 Aug; 10(8):. PubMed ID: 36002185
[TBL] [Abstract][Full Text] [Related]
19. 3D absorbed dose distribution estimated by Monte Carlo simulation in radionuclide therapy with a monoclonal antibody targeting synovial sarcoma.
Sarrut D; Badel JN; Halty A; Garin G; Perol D; Cassier P; Blay JY; Kryza D; Giraudet AL
EJNMMI Phys; 2017 Dec; 4(1):6. PubMed ID: 28101733
[TBL] [Abstract][Full Text] [Related]
20. A stylized computational model of the rat for organ dosimetry in support of preclinical evaluations of peptide receptor radionuclide therapy with (90)Y, (111)In, or (177)Lu.
Konijnenberg MW; Bijster M; Krenning EP; De Jong M
J Nucl Med; 2004 Jul; 45(7):1260-9. PubMed ID: 15235075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
